Mesoblast Cost Of Revenue from 2010 to 2024

MESO Stock  USD 10.11  0.07  0.69%   
Mesoblast Cost Of Revenue yearly trend continues to be very stable with very little volatility. Cost Of Revenue is likely to grow to about 24.3 M this year. During the period from 2010 to 2024, Mesoblast Cost Of Revenue quarterly data regression pattern had sample variance of 55.3 T and median of  24,410,000. View All Fundamentals
 
Cost Of Revenue  
First Reported
2012-09-30
Previous Quarter
9.7 M
Current Value
9.7 M
Quarterly Volatility
2.9 M
 
Yuan Drop
 
Covid
Check Mesoblast financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mesoblast's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.9 M, Interest Expense of 21.7 M or Selling General Administrative of 20.5 M, as well as many indicators such as Price To Sales Ratio of 106, Dividend Yield of 0.0 or PTB Ratio of 1.3. Mesoblast financial statements analysis is a perfect complement when working with Mesoblast Valuation or Volatility modules.
  
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Latest Mesoblast's Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of Mesoblast over the last few years. Cost of Revenue is found on Mesoblast income statement and represents the costs associated with goods and services Mesoblast provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Mesoblast's Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mesoblast's overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Very volatile
   Cost Of Revenue   
       Timeline  

Mesoblast Cost Of Revenue Regression Statistics

Arithmetic Mean22,710,947
Geometric Mean21,022,547
Coefficient Of Variation32.74
Mean Deviation5,626,105
Median24,410,000
Standard Deviation7,436,020
Sample Variance55.3T
Range27.2M
R-Value0.02
Mean Square Error59.5T
R-Squared0.0005
Significance0.94
Slope36,976
Total Sum of Squares774.1T

Mesoblast Cost Of Revenue History

202424.3 M
202315.7 M
202227.7 M
202130.8 M
202032.7 M
201925.3 M
201815.4 M

About Mesoblast Financial Statements

Mesoblast investors utilize fundamental indicators, such as Cost Of Revenue, to predict how Mesoblast Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue15.7 M24.3 M

Pair Trading with Mesoblast

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mesoblast position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will appreciate offsetting losses from the drop in the long position's value.

Moving against Mesoblast Stock

  0.87NKTX Nkarta IncPairCorr
  0.81VALN Valneva SE ADRPairCorr
  0.81MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.77AGL agilon healthPairCorr
  0.72JNJ Johnson Johnson Sell-off TrendPairCorr
The ability to find closely correlated positions to Mesoblast could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mesoblast when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mesoblast - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mesoblast to buy it.
The correlation of Mesoblast is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mesoblast moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mesoblast moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mesoblast can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
0.06
Quarterly Revenue Growth
(0.41)
Return On Assets
(0.05)
Return On Equity
(0.18)
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.